Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria
作者机构：From Instituto Evandro Chagas Ministério da Saúde do Brasil Ananindeua (N.N.C-.S. S.P.S. G.M.R.V.) Programa de Pós-Graduação em Biologia de Agentes Infecciosos e Parasitários (N.N.C.-S. E.J.M.S. F.P.C. G.M.R.V.) and Laboratório de Genética de Doenças Complexas (E.J.M.S. F.P.C.) Instituto de Ciências Biológicas and Laboratório de Farmacocinética de Drogas Antimaláricas Instituto de Ciências da Saúde (L.W.P.S. A.G.N.C.-M.) Universidade Federal do Pará Belém Secretaria de Saúde do Estado do Acre Cruzeiro do Sul (S.C.N. S.F.) and Grupo Técnico da Malária Coordenação-Geral de Vigilância de Zoonoses e Doenças de Transmissão Vetorial Departamento de Imunização e Doenças Transmissíveis Secretaria de Vigilância em Saúde Ministério da Saúde (P.B.M.) and Diretoria de Vigilância Epidemiológica Subsecretaria de Vigilância em Saúde Secretaria Estadual de Saúde do Distrito Federal (C.R.L.P.) Brasília - all in Brazil Epidemic Intelligence Service Center for Surveillance Epidemiology and Laboratory Services (S.-B.B.) and the Malaria Branch Division of Parasitic Diseases and Malaria Center for Global Health Centers for Disease Control and Prevention (S.-B.B. A.M.O.) - both in Atlanta and Instituto de Investigaciones en Ciencias Biomedicas Universidad Ricardo Palma Lima and Instituto de Enfermedades Tropicales Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas Chachapoyas (S.M.C.) - both in Peru.
出 版 物：《四川生理科学杂志》 (Sichuan Journal of Physiological Sciences)
年 卷 期：2022年第44卷第2期
页 面：347-347页
核心收录：
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金：Latin America and Caribbean Regional Malaria Program United States Agency for International Development, USAID, (NCT03610399)
摘 要：Background:In most of the Americas,the recommended treatment to prevent relapse of Plasmodium vivax malaria is primaquine at a total dose of 3.5 mg per kilogram of body weight,despite evidence of only moderate ***:In this trial conducted in Brazil,we evaluated three primaquine regimens to prevent relapse of *** malaria in children at least 5 years of age and in adults with microscopy-confirmed *** *** the patients received directly observed chloroquine for 3 days(total dose,25 mg per kilogram).Group 1 received a total primaquine dose of 3.5 mg per kilogram(0.5 mg per kilogram per day)over 7 days with unobserved administration;group 2 received the same regimen as group 1 but with observed administration;and group 3 received a total primaquine dose of 7.0 mg per kilogram over 14 days(also 0.5 mg per kilogram per day)with observed *** monitored the patients for 168 days.
维普期刊数据库